ArticleDiabetes, obesity & metabolism2025
Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed 780G according to patient characteristics.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic literature review and meta-analysis of real-world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes.Diabetes, obesity & metabolism · 2026Pooled it
- Glycemic Outcomes and Device Engagement Over 18 Months Following Initiation of Two Different Automated Insulin Delivery Systems in American Youth With Type 1 Diabetes.Diabetes technology & therapeutics · 2026Article
- Mind-glucose control interplay in type 1 diabetes: management of exam-related stress using the MiniMed™ 780G insulin pump among high school students.Diabetology & metabolic syndrome · 2026Article
- Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed 780G according to patient characteristics.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
aimsThis study aimed to compare 12-month metabolic outcomes in patients with type 1 diabetes (T1D) treated with either MiniMed 780G (Guardian 4) or Control-IQ (Dexcom G6) automated insulin delivery (AID) systems and identify interaction with patient characteristics. MATERIALS AND
methodsWe conducted a single-centre, retrospective study including all patients (aged ≥16) with T1D who were started on either MiniMed 780G or Control-IQ between January 2021 and October 2022 and continued for ≥12 months. We used propensity score matching to compare the average marginal effects between MiniMed 780G and Control-IQ regarding the primary outcome (time in range [TIR]) and secondary outcomes (time below range [TBR], glucose monitoring indicator [GMI] and coefficient of variation [CV]) after 12 months. We tested for interaction effects between baseline characteristics (age, sex, socio-professional background, body mass index, insulin daily dose, carbohydrate counting practice) and treatment effect.
resultsWe included 245 patients (58% women): 178 treated with Control-IQ and 67 with MiniMed 780G. The mean ± SD age and haemoglobin A1c were 39 ± 15 years and 8.7 ± 1.8% (72 ± 20 mmol/mol) respectively. In the propensity score-matched sample (n = 221), we observed significant differences in 12-month TIR (MiniMed 780G minus Control-IQ [95% CI]: 6.4 [3.4;9.5]), GMI (-0.42 [-0.59; -0.25]) and CV (-2.12 [-3.68; -0.55]), while TBR showed no significant difference (-0.04 [-0.47; +0.40]). The 12-month TIR difference was consistent across subgroups, including baseline carbohydrate counting characteristics.
conclusionMiniMed 780G is associated with moderate metabolic superiority compared to Control-IQ, without interaction with patient characteristics. These results suggest that neither model is more appropriate for certain populations, particularly patients without carbohydrate counting practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.